Is CELC or KURA more profitable?

Celcuity has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Kura Oncology's return on equity of -207.18% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Kura Oncology -384.30% -207.18% -45.17%

Does the media favor CELC or KURA?

In the previous week, Celcuity had 2 more articles in the media than Kura Oncology. MarketBeat recorded 8 mentions for Celcuity and 6 mentions for Kura Oncology. Celcuity's average media sentiment score of 1.26 beat Kura Oncology's score of 1.00 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KURA or ELVN?

In the previous week, Enliven Therapeutics had 2 more articles in the media than Kura Oncology. MarketBeat recorded 8 mentions for Enliven Therapeutics and 6 mentions for Kura Oncology. Enliven Therapeutics' average media sentiment score of 1.56 beat Kura Oncology's score of 1.00 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor KURA or RLAY?

In the previous week, Relay Therapeutics had 8 more articles in the media than Kura Oncology. MarketBeat recorded 14 mentions for Relay Therapeutics and 6 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 1.00 beat Relay Therapeutics' score of 1.00 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KURA or TNGX?

In the previous week, Tango Therapeutics had 4 more articles in the media than Kura Oncology. MarketBeat recorded 10 mentions for Tango Therapeutics and 6 mentions for Kura Oncology. Tango Therapeutics' average media sentiment score of 1.27 beat Kura Oncology's score of 1.00 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMLX or KURA?

In the previous week, Kura Oncology had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 6 mentions for Kura Oncology and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.31 beat Kura Oncology's score of 1.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kura Oncology (KURA) Competitors

$13.15 +0.04 (+0.31%)

As of 09/3/2026 04:00 PM Eastern

Compare

KURA vs. CELC, ELVN, RLAY, TNGX, and AMLX

Should you buy Kura Oncology stock or one of its competitors? Kura Oncology's main competitors and comparable companies include Celcuity (CELC), Enliven Therapeutics (ELVN), Relay Therapeutics (RLAY), Tango Therapeutics (TNGX), and Amylyx Pharmaceuticals (AMLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kura Oncology compare to Celcuity?

Celcuity (NASDAQ:CELC) and Kura Oncology (NASDAQ:KURA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Celcuity currently has a consensus price target of $154.55, indicating a potential upside of 60.27%. Kura Oncology has a consensus price target of $25.40, indicating a potential upside of 93.16%. Given Kura Oncology's higher probable upside, analysts plainly believe Kura Oncology is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Celcuity has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

63.3% of Celcuity shares are held by institutional investors. 13.3% of Celcuity shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Celcuity has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Kura Oncology's return on equity of -207.18% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Kura Oncology	-384.30%	-207.18%	-45.17%

In the previous week, Celcuity had 2 more articles in the media than Kura Oncology. MarketBeat recorded 8 mentions for Celcuity and 6 mentions for Kura Oncology. Celcuity's average media sentiment score of 1.26 beat Kura Oncology's score of 1.00 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celcuity has higher earnings, but lower revenue than Kura Oncology. Celcuity is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Kura Oncology	$67.48M	17.34	-$278.67M	-$3.37	N/A

Summary

Celcuity beats Kura Oncology on 8 of the 14 factors compared between the two stocks.

How does Kura Oncology compare to Enliven Therapeutics?

Kura Oncology (NASDAQ:KURA) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Kura Oncology has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Enliven Therapeutics has lower revenue, but higher earnings than Kura Oncology. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	17.34	-$278.67M	-$3.37	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

In the previous week, Enliven Therapeutics had 2 more articles in the media than Kura Oncology. MarketBeat recorded 8 mentions for Enliven Therapeutics and 6 mentions for Kura Oncology. Enliven Therapeutics' average media sentiment score of 1.56 beat Kura Oncology's score of 1.00 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Enliven Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Enliven Therapeutics' return on equity of -18.55% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Enliven Therapeutics	N/A	-18.55%	-18.09%

95.1% of Enliven Therapeutics shares are held by institutional investors. 7.6% of Kura Oncology shares are held by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kura Oncology presently has a consensus price target of $25.40, suggesting a potential upside of 93.16%. Enliven Therapeutics has a consensus price target of $75.00, suggesting a potential upside of 25.73%. Given Kura Oncology's higher probable upside, equities research analysts clearly believe Kura Oncology is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Enliven Therapeutics beats Kura Oncology on 9 of the 15 factors compared between the two stocks.

How does Kura Oncology compare to Relay Therapeutics?

Kura Oncology (NASDAQ:KURA) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Kura Oncology has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Kura Oncology currently has a consensus price target of $25.40, suggesting a potential upside of 93.16%. Relay Therapeutics has a consensus price target of $25.92, suggesting a potential upside of 36.33%. Given Kura Oncology's higher probable upside, equities analysts plainly believe Kura Oncology is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

97.0% of Relay Therapeutics shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Relay Therapeutics had 8 more articles in the media than Kura Oncology. MarketBeat recorded 14 mentions for Relay Therapeutics and 6 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 1.00 beat Relay Therapeutics' score of 1.00 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Relay Therapeutics' return on equity of -42.27% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Relay Therapeutics	N/A	-42.27%	-38.67%

Relay Therapeutics has lower revenue, but higher earnings than Kura Oncology. Relay Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	17.34	-$278.67M	-$3.37	N/A
Relay Therapeutics	$15.35M	271.39	-$276.48M	-$1.57	N/A

Summary

Relay Therapeutics beats Kura Oncology on 11 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to Tango Therapeutics?

Kura Oncology (NASDAQ:KURA) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Tango Therapeutics had 4 more articles in the media than Kura Oncology. MarketBeat recorded 10 mentions for Tango Therapeutics and 6 mentions for Kura Oncology. Tango Therapeutics' average media sentiment score of 1.27 beat Kura Oncology's score of 1.00 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has lower revenue, but higher earnings than Kura Oncology. Tango Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	17.34	-$278.67M	-$3.37	N/A
Tango Therapeutics	$62.38M	61.52	-$101.59M	-$0.85	N/A

Tango Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Tango Therapeutics' return on equity of -25.75% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Tango Therapeutics	N/A	-25.75%	-23.36%

79.0% of Tango Therapeutics shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kura Oncology has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Kura Oncology presently has a consensus target price of $25.40, indicating a potential upside of 93.16%. Tango Therapeutics has a consensus target price of $43.46, indicating a potential upside of 90.96%. Given Kura Oncology's higher possible upside, equities research analysts plainly believe Kura Oncology is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Tango Therapeutics beats Kura Oncology on 11 of the 15 factors compared between the two stocks.

How does Kura Oncology compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Kura Oncology (NASDAQ:KURA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Amylyx Pharmaceuticals currently has a consensus target price of $36.50, indicating a potential upside of 7.48%. Kura Oncology has a consensus target price of $25.40, indicating a potential upside of 93.16%. Given Kura Oncology's higher probable upside, analysts clearly believe Kura Oncology is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Amylyx Pharmaceuticals has higher revenue and earnings than Kura Oncology. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	43.31	-$144.74M	-$1.43	N/A
Kura Oncology	$67.48M	17.34	-$278.67M	-$3.37	N/A

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Kura Oncology had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 6 mentions for Kura Oncology and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.31 beat Kura Oncology's score of 1.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Amylyx Pharmaceuticals' return on equity of -52.92% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Kura Oncology	-384.30%	-207.18%	-45.17%

Summary

Amylyx Pharmaceuticals beats Kura Oncology on 11 of the 17 factors compared between the two stocks.

Get Kura Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KURA vs. The Competition

Export

Metric	Kura Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.17B	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-3.90	12.66	273.28	25.38
Price / Sales	17.34	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	24.35	16.29	12.89	6.14
Net Income	-$278.67M	-$22.72M	$3.47B	$349.01M
7 Day Performance	3.87%	0.34%	0.61%	-0.27%
1 Month Performance	38.86%	8.52%	5.73%	0.68%
1 Year Performance	61.75%	52.66%	25.37%	14.84%

Kura Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KURA Kura Oncology	3.7678 of 5 stars	$13.15 +0.3%	$25.40 +93.2%	+56.0%	$1.17B	$67.48M	N/A	130	Positive News
CELC Celcuity	2.7776 of 5 stars	$89.06 +0.7%	$154.55 +73.5%	+77.9%	$4.33B	N/A	N/A	40	Positive News Analyst Forecast
ELVN Enliven Therapeutics	2.8503 of 5 stars	$57.89 +0.1%	$75.00 +29.6%	+184.7%	$4.24B	N/A	N/A	50
RLAY Relay Therapeutics	2.9187 of 5 stars	$18.38 -2.1%	$25.92 +41.0%	+362.5%	$4.11B	$15.35M	N/A	330	Positive News
TNGX Tango Therapeutics	3.172 of 5 stars	$22.84 -2.1%	$43.46 +90.3%	+239.7%	$3.94B	$62.38M	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KURA) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kura Oncology (KURA) Competitors

KURA vs. CELC, ELVN, RLAY, TNGX, and AMLX

How does Kura Oncology compare to Celcuity?

Summary

How does Kura Oncology compare to Enliven Therapeutics?

Summary

How does Kura Oncology compare to Relay Therapeutics?

Summary

How does Kura Oncology compare to Tango Therapeutics?

Summary

How does Kura Oncology compare to Amylyx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kura Oncology (KURA) Competitors

KURA vs. CELC, ELVN, RLAY, TNGX, and AMLX

How does Kura Oncology compare to Celcuity?

Do analysts recommend CELC or KURA?

Which has more risk and volatility, CELC or KURA?

Do insiders & institutionals believe in CELC or KURA?

Is CELC or KURA more profitable?

Does the media favor CELC or KURA?

Which has stronger valuation & earnings, CELC or KURA?

Summary

How does Kura Oncology compare to Enliven Therapeutics?

Which has more risk and volatility, KURA or ELVN?

Which has higher valuation and earnings, KURA or ELVN?

Does the media prefer KURA or ELVN?

Is KURA or ELVN more profitable?

Do insiders and institutionals hold more shares of KURA or ELVN?

Do analysts rate KURA or ELVN?

Summary

How does Kura Oncology compare to Relay Therapeutics?

Which has more risk & volatility, KURA or RLAY?

Do analysts rate KURA or RLAY?

Do institutionals and insiders believe in KURA or RLAY?

Does the media favor KURA or RLAY?

Is KURA or RLAY more profitable?

Which has higher earnings and valuation, KURA or RLAY?

Summary

How does Kura Oncology compare to Tango Therapeutics?

Does the media refer more to KURA or TNGX?

Which has stronger earnings and valuation, KURA or TNGX?

Is KURA or TNGX more profitable?

Do institutionals & insiders have more ownership in KURA or TNGX?

Which has more risk and volatility, KURA or TNGX?

Do analysts rate KURA or TNGX?

Summary

How does Kura Oncology compare to Amylyx Pharmaceuticals?

Do analysts prefer AMLX or KURA?

Which has preferable earnings & valuation, AMLX or KURA?

Do institutionals and insiders believe in AMLX or KURA?

Does the media prefer AMLX or KURA?

Which has more risk and volatility, AMLX or KURA?

Is AMLX or KURA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools